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Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is
a serious complication associated with oral and intravenous
bisphosphonate therapy that adversely affects the quality of
life, producing significant morbidity.
Since the first description of bone necrosis in patients
receiving bisphosphonate therapy in 2003 [1], hundreds of
studies were published about this topic and various national
and international medical societies have published protocols
and guidelines. Nevertheless, there are still many controver-
sies regarding the classification,management, and prevention
of BRONJ.
Even the definition of BRONJ is still debated and changed
with the progress of knowledge and experience. According to
the original definition of the AAOMS (American Association
of Oral and Maxillofacial Surgery) [2, 3] “Patients may
be considered to have BRONJ if all of the following three
characteristics are present: (1) Current or previous treatment
with a bisphosphonate; (2) Exposed bone in the maxillofacial
region that has persisted for more than eight weeks; and (3) No
history of radiation therapy to the jaws.”
Following recognition of the nonexposed BRONJ clinical
variant, it became clear that the presence of exposed necrotic
bone in the oral cavity is just one of the possible clinical man-
ifestations of BRONJ and is not found in all BRONJ patients.
In 2012 the SICMF (Italian Society for Maxillofacial Surgery)
and the SIPMO (Italian Society of Oral Pathology and
Medicine) proposed a new definition [4]: “Bisphosphonate
related osteonecrosis of the jaw (BRONJ) is an adverse drug
reaction described as the progressive destruction and death of
bone that affects the mandible or maxilla of patients exposed
to the treatment with nitrogen-containing bisphosphonates, in
the absence of a previous radiation treatment.” Recently, this
definition was robustly supported by a cross-sectional study
on a large population of European patients with exposed
and non-exposed bisphosphonate-associated ONJ; where,
according to the traditional definition, only 76% of ONJ were
diagnosed, and diagnosis in the remaining 24% could not be
adjudicated, as they had several abnormal features relating
to the jaws but no visible necrotic bone. [5] In parallel, it
was demonstrated, in a large multicentre retrospective study,
that the severity of ONJ (i.e. the extent of bony disease) as
main guide to its management, can be correctly identified if
measured by computed tomography (CT), more accurately
than by clinical inspection and radiography as proposed by
several staging systems, including the widely-used American
Association of Oral and Maxillofacial Surgeons (AAOMS)
system [6].
Very recently the AAOMS recommends changing the
nomenclature of BRONJ [7]; the AAOMS favors the term
medication-related osteonecrosis of the jaw (MRONJ). The
change is justified to accommodate the growing number of
osteonecrosis cases involving the maxilla and mandible asso-
ciated with other antiresorptive (denosumab) and antiangio-
genic therapies.
The interesting and scientifically significant manuscripts
selected for publication in this special issue include review
articles, clinical studies, and research articles, which represent
an important contribution to analyze and try to solve current
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controversies in classification, management, and prevention
of BRONJ.
In the review article “Bisphosphonate-related osteonecrosis
of the jaw: a review of the literature” the authors offer a per-
spective on how dentists should manage patients on BPs, to
show the benefits of accurately diagnosing BRONJ and to
present diagnostic aids and treatments strategies for the con-
dition.
The role of infection in the etiology of bisphosphonate-
related osteonecrosis of the jaw (BRONJ) is poorly under-
stood.
In the review article “Is bisphosphonate-related osteonecro-
sis of the jaw an infection? A histological and microbiological
ten-year summary” the authors present a systematic review
of BRONJ histology and microbiology (including demo-
graphics, immunocompromised associations, clinical signs
and symptoms, disease severity, antibiotic and surgical treat-
ments, and recovery status) validating that infection should
still be considered a prime component in the multifactorial
disease.
The review article “Bisphosphonate associated osteonecro-
sis of the jaw: an update on pathophysiology, risk factors, and
treatment” is a narrative review of the literature; its aims are
to elaborate on the pathological mechanisms behind the con-
dition and also to gather an update on incidence, risk factors,
and treatment of bisphosphonate associated osteonecrosis of
the jaw.
The review article “Imaging findings of bisphosphonate-
related osteonecrosis of the jaws: a critical review of the quanti-
tative studies” offers a critical review of published information
on the imaging strategies used for diagnosing bisphosphonate
associated osteonecrosis of the jaw in patients taking intra-
venous bisphosphonates, pointing at the different method-
ologies and results of existing literature.
The existing BRONJ staging systems are numerous, but
not one is surgical oriented.
In the clinical study “New dimensional staging of bis-
phosphonaterelated osteonecrosis of the jaw allowing a guided
surgical treatment protocol: long-term follow-up of 266 lesions
in neoplastic and osteoporotic patients from the University
of Bari” a new dimensional stage classification, guiding the
surgical treatment of BRONJ patients, is proposed, and the
success rate of this new management is evaluated.
The most debated topic about BRONJ is therapy and
the most adequate procedure is far from being standardized.
Several approaches have been evaluated for the treatment
of patients who developed BRONJ and many management
strategies have been proposed. Nevertheless, it seems that
taking preventative measures is the most effective way to face
BRONJ.
In the clinical study “Platelet rich plasma in the treatment
of bisphosphonate-related osteonecrosis of the jaw: personal
experience and review of the literature” the authors considered
a group of patients affected by BRONJ with nonsurgical
therapy, surgical therapy, and surgical therapy with platelet
rich plasma (PRP) gel to evaluate its therapeutic effect in
promoting BRONJ wounds healing.
In the clinical study “Conservative treatment of bisphos-
phonaterelated osteonecrosis of the jaw in multiple myeloma
patients” the authors report a retrospective review of all their
MM patients who were treated with bisphosphonates and
developed BRONJ and discuss management issues.
The aim of the clinical study “Risk assessment of BRONJ in
oncologic patients treatedwith bisphosphonates: follow-up to 18
months” is tomonitor the BRONJ level of risk in patients with
cancer, according to a preventive clinical protocol, which is
firstly aimed at reducing risk factors such as the periodontal
infections.
In the research article “The “CROMa” project: a care path-
way for clinical management of patients with bisphosphonate
exposure” the authors describe the activity of “CROMa” (Co-
ordination of Research on Osteonecrosis of the Jaws) project
of “Sapienza” University of Rome evaluating the risk variables
of patients with past, present, or planned BP exposure, treated
with periodontics, oral surgery, and operative dentistry pro-
cedures in order to treat or prevent BRONJ.
We sincerely hope that the readers can enjoy this special
issue and improve their knowledge about BRONJ; we wish
that the articles published will encourage further research on
classification, management, and prevention of BRONJ.
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